Galectin Therapeutics Inc.
GALT · Nasdaq · United States
Share price · GALT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when GALT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 9 Nov 2026+10.2%
Nothing announced by GALT that day or the session before.
- 13 Aug 2026+12.4%
- 14 Jul 2026+16.1%
Nothing announced by GALT that day or the session before.
- 13 Jul 2026+13.3%
Nothing announced by GALT that day or the session before.
- 26 Jun 2026+18.0%
Nothing announced by GALT that day or the session before.
- 24 Jun 2026+25.6%
- 23 Jun 2026+11.4%
- 26 May 2026+11.6%
Nothing announced by GALT that day or the session before.
- 21 May 2026+14.0%
Nothing announced by GALT that day or the session before.
- 16 Apr 2026-11.7%
Nothing announced by GALT that day or the session before.
Share of unusual movement by asset
For each asset, the share of GALT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | Galectin-3Polysaccharide | MASH / NASH NASH Cirrhosis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $2.1M | $13M | $9.1M-$2.4M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $0 | $2.2M | $14M | $5.1M | report ↗ |
| 2025-Q3 | — | $2.6M | $12M | $8.2M-$3.5M operating cash flow | report ↗ |
| 2025-Q2 | — | $3.3M | $14M | $7.5M-$6.6M operating cash flow | report ↗ |
| 2025-Q1 | — | $6.5M | $7.4M | $9.6M-$7.7M operating cash flow | report ↗ |
| 2024-Q3 | — | $7.6M | $27M | $11M-$8.5M operating cash flow | report ↗ |
| 2024-Q2 | — | $9.8M | $26M | $12M-$8.3M operating cash flow | report ↗ |
| 2024-Q1 | — | $8.1M | $24M | $11M-$12M operating cash flow | report ↗ |
| 2023-Q3 | — | $7.7M | $20M | $10M-$7.6M operating cash flow | report ↗ |
| 2023-Q2 | — | $7.4M | $18M | $9.1M-$9.8M operating cash flow | report ↗ |
| 2023-Q1 | — | $8.8M | $18M | $12M-$11M operating cash flow | report ↗ |
| 2022-Q3 | — | $6.6M | $16M | $8.6M-$8.3M operating cash flow | report ↗ |
| 2022-Q2 | — | $8.1M | $24M | $9.6M-$7.4M operating cash flow | report ↗ |
| 2022-Q1 | — | $8.1M | $32M | $9.9M-$8.0M operating cash flow | report ↗ |
| 2021-Q3 | — | $6.6M | $37M | $8.5M-$5.0M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $14M | $18M | $7.7M-$24M operating cash flow | report ↗ |
For FY2025, Galectin Therapeutics did not disclose revenue. R&D spend was $14.29M, down 60.9% YoY from $36.57M in 2024. Cash and equivalents stood at $17.72M, and the company reported a net loss of $30.84M.
Management guided that current cash, including a $10M line of credit from its chairman, is expected to fund planned operations through April 2027. In the belapectin NAVIGATE trial for MASH cirrhosis and portal hypertension, the 2 mg/kg dose reduced varices incidence by 43.2% versus placebo in the intent-to-treat population without reaching statistical significance on the composite endpoint, by 49.3% in the per-protocol population (nominal p=0.04), and by 68.1% in U.S. per-protocol patients (p=0.02); safety was similar across groups with no drug-related serious adverse events. Additional biomarker analyses were reported, abstracts were accepted for EASL 2026 including an oral presentation, and an FDA meeting is planned for Q2 2026.
Insider transactions
Open-market activity, trailing 12 months: 6 purchases ($65K), 39 sales ($4.9M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-07-31 | Uihlein Richard E · director, 10% owner | Option exercise | 31,825,235 | $3.00 | $95.5M | Form 4 |
| 2026-07-31 | Uihlein Richard E · director, 10% owner | Option exercise | 2,550,932 | $4.05 | $10.3M | Form 4 |
| 2026-07-31 | Uihlein Richard E · director, 10% owner | Option exercise (derivative) | — | $95475705.00 | — | Form 4 |
| 2026-07-31 | Uihlein Richard E · director, 10% owner | Option exercise (derivative) | — | $10331275.00 | — | Form 4 |
| 2026-07-14 | Jamil Khurram · Chief Medical Officer | Option exercise | 16,250 | $3.04 | $49K | Form 4 |
| 2026-07-14 | Jamil Khurram · Chief Medical Officer | Open-market sale | 16,250 | $5.13 | $83K | Form 4 |
| 2026-07-14 | Jamil Khurram · Chief Medical Officer | Option exercise (derivative) | 16,250 | — | — | Form 4 |
| 2026-06-29 | Shlevin Harold H. · director | Option exercise | 22,268 | $1.23 | $27K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 98 reporting institutions held 13.9M shares ($37.8M, 13.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 1,966,542 | $5.5M |
| 2 | MARSHALL WACE, LLP | 1,219,912 | $3.4M |
| 3 | OSAIC HOLDINGS, INC. | 1,122,670 | $3.1M |
| 4 | BlackRock, Inc. | 799,237 | $2.2M |
| 5 | MILLENNIUM MANAGEMENT LLC | 798,434 | $2.2M |
| 6 | Wealthspire Advisors, LLC | 721,788 | $2.0M |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 612,786 | $1.7M |
| 8 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 555,702 | $1.6M |
| 9 | TWO SIGMA INVESTMENTS, LP | 467,063 | $1.3M |
| 10 | COMMONWEALTH EQUITY SERVICES, LLC | 367,113 | $1.0M |
| 11 | VANGUARD FIDUCIARY TRUST CO | 304,241 | $849K |
| 12 | CITADEL ADVISORS LLC | 290,360 | $810K |
| 13 | LPL Financial LLC | 267,200 | $745K |
| 14 | Vivaldi Capital Management LP | 258,584 | $721K |
| 15 | STATE STREET CORP | 258,432 | $721K |